ArticleFrontiers in pharmacology2024

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer.

Gengwei Huo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.